Infant Bacterial Therapeutics AB (FRA:9IB) EPS without NRI: €-0.49 (TTM As of Mar. 2026)

Infant Bacterial Therapeutics AB  (FRA:9IB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Infant Bacterial Therapeutics AB EPS without NRI Related Terms

The historical data trend for Infant Bacterial Therapeutics AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB EPS without NRI Chart

Infant Bacterial Therapeutics AB Annual Data
	Trend	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24	Dec25
EPS without NRI		Get a 7-Day Free Trial					-0.39	-0.53	-0.89	-0.88	-0.45

Infant Bacterial Therapeutics AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS without NRI	Get a 7-Day Free Trial															-0.11	-0.13	-0.07	-0.13	-0.16

FRA:9IB vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's PE Ratio without NRI falls into.

Infant Bacterial Therapeutics AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB Business Description